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and curtail the development of drug resistance. Innovations in
reinforcement of this strategy should further facilitate its deliv-
ery and enhance its effectiveness. However, established MDR-TB
is notoriously difﬁcult to treat, and necessitates the use of alter-
native speciﬁc anti-TB chemotherapy regimens. These regimens
comprise combination use of second-line and third-line anti-TB
drugs, that are generally more costly and toxic, and have to
be given for longer durations – usually in the range of 18–24
months. The ﬂuoroquinolones, better tolerated by patients, have
a pivotal role in MDR-TB treatment. Optimal delivery of these
treatment regimens mandates a programmatic basis which is now
included under the Stop-TB Drug-Resistance Programme(s). The
key components embrace political commitment, quality-assured
drug susceptibility testing, reliable supply of quality drugs, de-
livery of chemotherapy under directly observed settings, and a
sound recording and reporting system to monitor the individual
treatment outcome of patient and overall performance of the
TB control programme. Adjunctive surgery in selected MDR-TB
patients help to improve their treatment success. Further ex-
ploration is required regarding the use of immunotherapy. The
recent emergence of extensively drug-resistant TB (XDR-TB),
representing MDR-TB with additional bacillary resistance to ﬂuo-
roquinlones and one or more of the second-line injectable drugs –
kanamycin, amikacin and capreomycin, poses a serious challenge
to the global control of TB. Given the escalating size of the
problem of MDR-TB and XDR-TB worldwide, gigantic instillation
of resources is required for control of this formidable challenge,
largely through more accurate and rapid drug susceptibility
testing (especially for rifampicin and ﬂuoroquinolone), regular
drug-resistance surveillance, development of new anti-TB drugs
and other therapeutic modalities, intensive infection control, es-
pecially in HIV care settings, as well as strengthening of currently
functioning DOTS and Drug-Resistance Programmes.
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Objective: In order to take an insight into the treatment of
AIDS and tuberculosis (TB) co-infection, we made a retrospective
study in 9 hospitals in mainland China.
Method: According to the uniﬁed questionary, 241 cases with
such co-infection were enrolled and the data with respect to
therapy and prognosis were analysed.
Result: Pulmonary TB accounted for 59.3%, extra pulmonary TB
for 21.2% and both for 19.5% of the patients. 76.8% of the 241
cases had a CD4 cell count<200 and 58.5%<100. 80.5% of the pa-
tients were treated with anti-tuberculosis medication and 69.7%
with highly active antiretroviral therapy. The regimen of anti-TB
was comprised of two-stage medication. The ﬁrst stage includes
INH, RFP, PZA and EMB while the second stage medication uses
INH and RFP. 203 (84.2%) were still alive and 38 (15.8%) died.
Conclusion: The combination regimen of many anti-TB agents
is potent to curing AIDS/TB co-infection. Generally, 4 anti-TB
agents used in ﬁrst stage for two monthes and 2 drugs used for
anti-TB in second stage for 4 monthes. If the tuberculosis was not
cured by the above regimen, the treatment of 2 agents regimen
should last for 7 monthes. The mortality (15.8%) was high even
with HAART and anti-tuberculosis therapy.
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The emergence of extensively drug resistant tuberculosis (XDR-
TB) strains among multi drug resistant tuberculosis (MDR-TB)
patients is widely considered as a serious threat to global TB
control. The diagnosis of XDR-TB is hampered by the absence of
effective and rapid diagnostic techniques for antimycobacterial
susceptibility testing especially in high-burden countries. The
advances in molecular technologies (eg. PCR, reverse hybridiza-
tion and DNA sequencing) represents a rapid diagnostic tool
due to their superior accuracy and cost-effectiveness in the de-
tection of mutations associated with drug resistance. Multiplex
allele-speciﬁc (MAS)-PCRs of mabA (3-ketoacyl reductase) and
katG (catalase-peroxidase) genes identify isoniazid resistance
while rifampin and oﬂoxacin resistance can be detected by PCR-
sequencing of rpoB (RNA polymerase β–subunit) and gyrA (gyrase
A) genes respectively. Direct detection of drug resistance asso-
ciated mutations in mabA, katG, rpoB, and gyrA genes indicate
potential application for rapid diagnosis of XDR-TB, resulting in a
net time gain of 1 to 2-months over conventional antimycobac-
terial susceptibility testing so that early initiation of anti-TB
therapy and management of patients can be initiated.
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Understanding of pharmacokinetic-pharmacodymic (PK-PD) prin-
ciples has revolutionized our understanding of anti-infective
dosing design. Apart from recognizing the pharmacokinetic prop-
erties (absorption, distribution, metabolism and excretion) of
an antibiotic, the pharmacodymics (such MIC distribution), the
PK-PD interactions such as concentration dependency and time
dependency are all of paramount importance in the design of
appropriate therapy. In the treatment of tuberculosis, as the
treatment duration is usually prolonged, ensuring compliance is
often problematic. Poor compliance will lead to failure of treat-
ment, relapse of disease, and emergence of multi-drug or even
extended-drug resistance. The recognition of speciﬁc property of
a drug, such as persistent effect (also known as post-antibiotic
effect) allows design of single daily dose, or even extended
interval dosing regimen. In vitro models, animal models and clin-
ical trials have ﬂourished in recent years. Rifampicin, isoniazid,
pyrazinamide, ﬂuoroquinolones, oxazolidinone all have individ-
ual PK-PD characteristics in terms of MIC90, Cmax/MIC and AUIC.
These had lead to the development of possible twice weekly or
even weekly regimens, as well as deﬁning mutation selection
window and its protection by the use of appropriate combination
therapy. Improvement in the understanding of these treatment
strategies, will not only maximize the therapeutic efﬁcacy, but
also improve compliance and also long term treatment outcomes.
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Identiﬁcation of latent TB infection (LTBI) is an important health
policy issue. In BCG vaccination countries, however, tuberculin
skin test (TST) is difﬁcult to be used as a predictor of TB infec-
tion. Recent application of interferon-γ blood tests has improved
the diagnosis. In this study, we applied and compared these tests
to identify the latent TB infection.
Materials and Methods: This was a prospective, double-
matched, cohort study in which 32 ESRD patients and 32 age-
matched, healthy controls were enrolled. The TST and two new
interferon-γ blood tests, QuantiFERON-TB Gold QFT-G) and T-
SPOT.TB (ELISPOT), were performed. The subjects were followed
